Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Agensys, Astellas deal

Astellas will acquire Agensys for $387 million in cash, net of Agensys' $30 million in cash.

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE